Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 31.43 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $1.499 million which missed the analyst consensus estimate of $2.279 million by 34.23 percent. This is a 43.79 percent decrease over sales of $2.667 million the same period last year.